MedImmune in Cambridge UK is reaching out to academics and biotech companies in a bid to improve the industry’s poor neuroscience track record.
Together with AstraZeneca in Boston, Massachusetts, MedImmune – the global biologics unit of AstraZeneca – is setting up a collaborative unit at its Granta Park HQ with the aim of producing drugs to treat neurodegenerative conditions, long term pain and neuropsychiatric conditions.
Iain Chessell, vice-president R & D Neuroscience said: “There have been no new approvals of completely novel mechanisms for treating pain for at least a decade – if not more – and current treatment only works in a third to half of patients.